Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast

International Journal of Surgical Pathology

Volumn 11, Issue 1, 2003, Pages 29-34

  Koukourakis, Michael I ^a,b   Manolas, Costantinos ^a   Minopoulos, George ^a   Giatromanolaki, Alexandra ^a   Sivridis, Efthimios ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Tumor and Angiogenesis Research Group Alexandroupolis   (Greece)

Author keywords

Angiogenesis; Breast cancer; C erbB 2; Prognosis

Indexed keywords

ESTROGEN RECEPTOR; GENE PRODUCT; ONCOPROTEIN;

ANGIOGENESIS; ARTICLE; BREAST CARCINOMA; BREAST DUCT; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS;

EID: 0037281458     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689690301100107     Document Type: Article

References (29)

1. Talks KL, Harris AL. Current status of antiangiogenic factors. Br J Haematol 109:477-489, 2000
2. Konerding MA, Miodonski AJ, Lametschwandtner A. Microvascular corrosion casting in the study of tumor vascularity: A review. Scanning Microsc 9:1233-1243, 1995
3. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
4. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
5. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat 52:159-173, 1998
6. Peroulis I, Jonas N, Saleh M. Antiangiogenic activity of endostatin inhibits c6 glioma growth. Int J Cancer 97:839-845, 2002
7. Chekenya M, Hjelstuen M, Enger PO, Thorsen F, Jacob AL, Probst B, Haraldseth O, Pilkington G, Butt A, Levine JM, Bjerkvig R. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J 16:586-588, 2002
8. Klijanienko J, el-Naggar AK, de Braud F, Rodriguez-Peralto JL, Rodriguez R, Itzhaki M, Russo A, Janot F, Luboinski B, Cvitkovic E. Tumor vascularization, mitotic index, histopathologic grade, and DNA ploidy in the assessment of 114 head and neck squamous cell carcinomas. Cancer 75:1649-1656, 1995
9. Giatromanolaki A, Koukourakis MI, Kakolyris S, Turley H, O'Byrne K, Scott PA, Pezzella F, Georgoulias V, Harris AL, Gatter KC. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 4:3017-3024, 1998
10. Aranda FI, Laforga JB. Microvessel quantitation in breast ductal invasive carcinoma. Correlation with proliferative activity, hormonal receptors and lymph node metastases. Pathol Res Pract 192:124-129, 1996
11. Jacquemier JD, Penault-Llorca FM, Bertucci F, Sun ZZ, Houvenaeghel GF, Geneix JA, Puig BD, Bardou VJ, Hassoun JA, Birnbaum D, Viens PJ. Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: A multiparametric and immunohistochemical analysis. J Pathol 184:130-135, 1998
12. Charpin C, Devictor B, Bergeret D, Andrac L, Boulat J, Horschowski N, Lavaut MN, Piana L. CD31 quantitative immunocytochemical assays in breast carcinomas. Correlation with current prognostic factors. Am J Clin Pathol 103:443-448, 1995
13. Yen L, You XL, Al Moustafa AE, Batist G, Hynes NE, Mader S, Meloche S, Alaoui-Jamali MA. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 19:3460-3469, 2000
14. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995-4004, 2001
15. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC, Harris AL. Relation of hypoxia-inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer 85:881-890, 2001
16. Koukourakis MI, Giatromanolaki A, O'Byrne KJ, Cox J, Krammer B, Gatter KC, Harris AL. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin Exp Metastasis 17:545-554, 1999
17. Yonenaga F, Takasaki T, Ohi Y, Sagara Y, Akiba S, Yoshinaka H, Aikou T, Miyadera K, Akiyama S, Yoshida H. The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer. Pathol Int 48:850-856, 1998
18. Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP. Pathobiologic findings in DCIS of the breast: Morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70:303-316, 2001
19. Bevilacqua P, Barbareschi M, Verderio P, Boracchi P, Caffo O, Dalla Palma P, Meli S, Weidner N, Gasparini G. Prognostic value of intratumoral microvessel density, a measure of tumor angiogenesis, in node-negative breast carcinoma - results of a multiparametric study. Breast Cancer Res Treat 36:205-217, 1995
20. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K, Harris AL. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
21. Ali SH, O'Donnell AL, Balu D, Pohl MB, Seyler MJ, Mohamed S, Mousa S, Dandona P. Estrogen receptor-alpha in the inhibition of cancer growth and angiogenesis. Cancer Res 60:7094-7098, 2000
22. Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: Association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch 438:470-477, 2001
23. Hansen S, Grabau DA, Sorensen FB, Bak M, Vach W, Rose C. Vascular grading of angiogenesis: Prognostic significance in breast cancer. Br J Cancer 82:339-347, 2000
24. Gasparini G, Toi M, Biganzoli E, Dittadi R, Fanelli M, Morabito A, Boracchi P, Gion M. Thrombospondin-1 and -2 in node-negative breast cancer: Correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis. Oncology 60:72-80, 2001
25. Kato T, Kameoka S, Kimura T, Nishikawa T, Kasajima T. Angiogenesis and blood vessel invasion as prognostic indicators for node-negative breast cancer. Breast Cancer Res Treat 65:203-215, 2001
26. Colpaert C, Vermeulen P, Jeuris W, van Beest P, Goovaerts G, Weyler J, VanDam P, Dirix L, Van Marck E. Early distant relapse in "node-negative" breast cancer patients is not predicted by occult axillary lymph node metastases, but by the features of the primary tumor. J Pathol 193:442-449, 2001
27. Vincent-Salomon A, Carton M, Zafrani B, Freneaux P, Nicolas A, Massernin B, Fourquet A, Clough K, Pouillart P, Sastre-Garau X. Long-term outcome of small size invasive breast carcinomas independent from angiogenesis in a series of 685 cases. Cancer 92:249-256, 2001
28. Vermeulen PB, Libura M, Libura J, O'Neill PJ, van Dam P, Van Marck E, Van Oosterom AT, Dirix LY. influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treat 42:165-172, 1997
29. Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL, Dirix LY. Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 32:2474-2484, 1996